Ligase-Conditioned Junction Tree Variational Autoencoder

Gold definitionUpdated Apr 2, 2026

Definition

The Ligase-Conditioned Junction Tree Variational Autoencoder (LC-JT-VAE) is an AI-assisted drug design model that generates novel, ligase-specific small molecules. It incorporates protein sequence embeddings and torsional angle-aware molecular graphs to facilitate targeted protein degradation, particularly for neurodegenerative diseases.

At a glance

Executive summary

The Ligase-Conditioned Junction Tree Variational Autoencoder (LC-JT-VAE) is an AI tool for designing new drugs that specifically target and degrade harmful proteins, like those involved in Alzheimer's disease. It works by generating custom small molecules that can 'glue' disease proteins to natural cellular machinery for disposal, offering a new way to create therapies.

TL;DR

An AI model that designs specific small molecules to help the body get rid of bad proteins linked to diseases like Alzheimer's.

Key points

Generates novel, ligase-specific small molecules by conditioning a VAE on protein embeddings and molecular graphs.
Solves the challenge of designing targeted protein degraders for diseases like Alzheimer's.
Used by researchers and drug developers in AI-assisted drug discovery for neurodegenerative diseases.
Unlike traditional drug discovery that screens existing libraries, LC-JT-VAE generates de novo compounds tailored to specific ligase interactions.
Represents a growing trend in generative AI for precision medicine and targeted protein degradation (TPD) therapies.

Use cases

Designing molecular glues for Abeta-42 degradation in Alzheimer's disease research.
Developing targeted protein degraders for other neurodegenerative conditions involving protein misfolding.
Accelerating the discovery of compounds that modulate the ubiquitin-proteasome system for various therapeutic areas.
Generating novel chemical scaffolds for E3 ligase-mediated protein degradation.
Personalized medicine approaches where specific ligase interactions are desired for patient-specific protein targets.

Also known as

LC-JT-VAE, Ligase-Conditioned VAE, JT-VAE for TPD